WINTW Stock Price, Chart, Stats & News

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company primarily focused on developing innovative therapies for acute cardiovascular conditions. Its robust pipeline features several key therapeutic candidates at various clinical stages: Istaroxime, their flagship compound, is currently undergoing Phase 2b clinical trials for acute decompensated heart failure and Phase 2a trials for early cardiogenic shock. Beyond cardiovascular indications, Windtree is advancing two surfactant-based therapies: AEROSURF, an aerosolized KL4 surfactant, is in Phase 2b for respiratory distress syndrome in premature infants.